Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Rapid Leishmania Diagnostic Receives FDA Clearance

by Global Biodefense Staff
December 1, 2014
Sand Fly Which Can Cause Leishmaniasis

Phlebotomus spp. sand flies are blood-sucking insects, which are very small, and sometimes act as the vectors for various diseases such as leishmaniasis, and bartonellosis. Credit: CDC/WHO

Phlebotomus spp. sand flies are a vector for leishmaniasis. Credit: CDC/WHO

A hand-held “dipstick” device for the rapid diagnosis of cutaneous leishmaniasis, co-developed by the U.S. Army and InBios International, has received clearance from the Food and Drug Administration (FDA).

Development of the device was backed by the U.S. Army Small Business Innovation Research (SBIR) Program, which allowed InBios the opportunity to provide an innovative research and development solution in response to a critical Army need: rapid diagnosis of cutaneous leishmaniasis in an operational setting.

The CL Detect™ Rapid Test provides results within 30 minutes, a significant improvement over the current process.

“Diagnosing CL often requires samples to be shipped to and tested at stateside laboratories. This is important because rapid diagnosis means treatment can begin immediately,” said Lt. Col. Jeanne Norwood, product manager for the CL Detect at the U.S. Army Medical Materiel Development Activity (USAMMDA).

Cutaneous leishmaniasis is a parasitic disease that causes disfiguring lesions. It is mainly found in the tropical and subtropical areas in the Middle East, southwest Asia, the Mediterranean coast, sub-Saharan Africa, Mexico, and Central and South America, and it is spread through the bite of infected sand flies. It places 350 million people at risk worldwide, with 1.5 million new cases emerging annually, including U.S. service members serving abroad.

For the DoD, the CL Detect will serve as an important asset in the general diagnosis of skin lesions, distinguishing cutaneous leishmaniasis from other important infectious diseases with similar symptoms. It will allow implementation of appropriate treatments which can reduce the severity of scarring, reduce lost duty time and improve healthcare and morale for U.S. military personnel in numerous areas of operations.

“Dedicated product managers drive transformational results by partnering with small businesses. This project is a great example of the cutting edge impact small business innovators can bring to military health through the U.S. Army SBIR Program,” said JR Myers, project manager for USAMRMC SBIR.

InBios International, Inc. is a medical device manufacturer located in Seattle, Washington.

Tags: LeishmaniasisPOC Diagnostics

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC